Generic Name:Pembrolizumab Indications Pemro is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma: Non-Small Cell Lung Cancer (NSCLC): Small Cell Lung Cancer (SCLC): for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Head and Neck Squamous Cell Cancer (HNSCC): […]